Ron Newbold

Vice President, External R&D Innovation, Pfizer


Ron Newbold is Vice President, External R&D Innovation (ERDI) for Pfizer Worldwide Research and Head of Global Scouting.  Ron and his group identify new and support established Worldwide Research & Development (WRD) alliances with numerous universities and biotechnology
companies across the globe.  Ron also supports Pfizer’s investments into early-stage technologies through the Pfizer Seed Fund, enabling scientific opportunities in alignment with Pfizer’s research interests and in partnership with Pfizer Ventures.  This fund is intended to help spin out new companies from universities as they are formed, engaging
Pfizer scientists as collaborators and advisors while investing
alongside other funds in this innovative arena.  

After receiving his PhD in Organic Chemistry from the University of Rochester and a postdoctoral fellowship with Nobel Laureate E.J. Corey at Harvard University, he joined Merck Research Laboratories where he founded and led their Strategic Research Initiatives licensing team from
1996-2004.  Following 14 years with Merck, Ron led business development for Sentigen Biosciences (founded by 2004 Nobel Laureate Richard Axel of Columbia University); Celldex Therapeutics; and Auspex Pharmaceuticals, where he served as Chief Business Officer, prior to joining Pfizer in 2010.  Ron has over 20 years of experience in business development and licensing in the pharmaceutical and biotechnology industries.  He has been involved on both sides of M&A transactions,
helping  to integrate smaller companies into the pharmaceutical culture and ensuring the new employees are welcomed into the larger organization. He has extensive alliance management experience, and manages a team of scientists in over 10 countries who evaluate and propose partnerships of scientific value. He is a Board Observer to Lumena Pharmaceuticals, Ecini Therapeutics, and Neoantigenics, and a Scientific Advisory Board member to Neomed, in addition to his Board role for the Licensing and Ventures Group at the University of Virginia.

Ph.D. (Synthetic Organic Chemistry) University of Rochester; M.B.A., Columbia University; B.S. (Chemistry) Union College